Lodelcizumab Biosimilar - Research Grade

Human

PCSK9

>1mg/ml

IgG1 - kappa

CHO Cells

Alirocumab Biosimilar - Research Grade (ICH4016), Evolocumab Biosimilar - Research Grade (ICH4023), Bococizumab Biosimilar - Research Grade (ICH5142), Ebronucimab Biosimilar - Research Grade (ICH5498), Frovocimab Biosimilar - Research Grade (ICH5558), Ongericimab Biosimilar - Research Grade (ICH5733), Ralpancizumab Biosimilar - Research Grade (ICH5801), Recaticimab Biosimilar - Research Grade (ICH5808), Tafolecimab Biosimilar - Research Grade (ICH5894)

https://www.imgt.org/mAb-DB/

ICH3002

Q8NBP7

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of lodelcizumab, supplied for research use only. It is built around the same target as the originator anti-PCSK9 antibody, an IgG1-kappa immunoglobulin directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9, UniProt Q8NBP7). It is not the clinical drug and is not intended for human or veterinary use. The molecule is a useful tool for laboratories studying PCSK9 biology and LDL-receptor recycling, and for teams developing or benchmarking PCSK9-directed biologics. Typical applications include use as a binding and neutralisation reference reagent, as a positive or isotype-matched control in assay development, as a capture or detection tool in ELISA and other immunoassays, and as a standardised input for in-vitro potency and comparability work. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg available) and in bulk milligram-to-gram quantities to support screening, assay validation, and preclinical characterisation. Format is unconjugated, allowing downstream labelling or conjugation as needed. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a secreted serine protease and a master regulator of plasma LDL cholesterol. Expressed mainly in liver, intestine, and kidney, the ~692-residue protein comprises a prosegment, a subtilisin-like catalytic domain, and a C-terminal cysteine-histidine-rich domain. After autocatalytic cleavage, the prosegment remains bound and the enzyme is secreted as a catalytically inactive complex. Circulating PCSK9 binds the EGF-A domain of the LDL receptor (LDLR) at the hepatocyte surface; rather than inhibiting the receptor directly, this binding redirects the LDLR-PCSK9 complex to lysosomal degradation instead of recycling, reducing surface LDLR and raising plasma LDL-C. Gain-of-function variants cause autosomal dominant hypercholesterolemia, whereas loss-of-function variants lower LDL-C and cardiovascular risk, validating PCSK9 as a therapeutic target. PCSK9 also engages other receptors including VLDLR and LRP8/ApoER2.

Neural apoptosis-regulated convertase 1, NARC-1, Proprotein convertase 9, PC9, Subtilisin/kexin-like protease PC9, Proprotein convertase subtilisin/kexin type 9

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks